Table 2.
Descriptives of antigen expression prior and 48-72 hours following subcutaneous denosumab administration. CD14/C23/CD123/CD16 stainings. Thirty postmenopausal osteoporotic women under treatment with denosumab.
| 1st measuremet (Baseline) | 2nd measurment | |||
|---|---|---|---|---|
| Staining | Mean | Std. Deviation | Median | IQR |
| CD14+/CD23+ | 2,6546 | 3,81430 | 9,9927 | 20,78235 |
| CD14+/CD23- | 59,0086 | 30,06067 | 69,8865 | 23,04598 |
| CD14-/CD23+ | ,9821 | 1,00949 | 1,6569 | 1,42718 |
| CD14-/CD23- | 25,9381 | 22,39671 | 23,2454 | 19,53608 |
| CD14+/CD123+ | 9,0567 | 11,86702 | 17,3707 | 17,27212 |
| CD14+/CD123- | 62,2593 | 19,98991 | 73,0904 | 20,50811 |
| CD14-/CD123+ | 6,5161 | 4,14880 | 3,9878 | 4,56302 |
| CD14-/CD123- | 14,0196 | 11,19632 | 13,6048 | 12,44166 |
| CD14+/CD16+ | 15,6682 | 18,63325 | 8,2926 | 4,60213 |
| CD14+/CD16- | 65,1189 | 22,28524 | 56,0948 | 24,47873 |
| CD14-/CD16+ | 10,0671 | 6,55533 | 15,4348 | 13,83929 |
| CD14-/CD16- | 9,1775 | 10,43060 | 6,4259 | 6,26783 |
2nd measurement, 48-72 hours following subcutaneous denosumab administration.